In some embodiments, the compositions and methods relate to compounds isolated from plants in the Salviniaceae family, pharmaceutical compositions comprising the same, and methods of using the same.

The invention generally relates to conducting reactions in Leidenfrost-levitated droplets.

The invention generally relates to conducting reactions in Leidenfrost-levitated droplets.

The present invention relates to epoxy curing agent compositions comprising naphthol and naphthol derivatives in combination with at least one polyamine having three or more active amine hydrogens, and use of these curing agents as hardener for epoxy resins. These curing agent compositions may be used to cure, harden and/or crosslink an epoxy resin.

The present invention relates to epoxy curing agent compositions comprising naphthol and naphthol derivatives in combination with at least one polyamine having three or more active amine hydrogens, and use of these curing agents as hardener for epoxy resins. These curing agent compositions may be used to cure, harden and/or crosslink an epoxy resin.

Described is the use of benzotropolone and their derivatives, especially the compounds of formula (1); wherein R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 independently of one another are hydrogen; OH; C.sub.1-C.sub.30alkyl, C.sub.2-C.sub.30al-kenyl, C.sub.1-C.sub.30alkoxy, C.sub.3-C.sub.12cycloalkyl or C.sub.1C.sub.30hydroxyalkyl, which may be substituted by one or more E and/or interrupted by one or more D; C.sub.6-C.sub.20aryl, which may be substituted by one or more G; C.sub.4-C.sub.20heteroaryl, which may be substituted by one or more G, C.sub.2-C.sub.18alkenyl, C.sub.2-C.sub.18alkynyl, C.sub.7-C.sub.25aralkyl, CN, or COR.sub.17; C.sub.1-C.sub.30mono- or dialkylamino; COR.sub.9; COOR.sub.9; CONR.sub.9R.sub.10; CN; SO.sub.2R.sub.9; OCOOR.sub.9; OCOR.sub.9; NHCOOR.sub.9; NR.sub.9COR.sub.10; NH.sub.2; *(CO)NH(CH.sub.2).sub.n1(PO)(OR.sub.11).sub.2; (CO)O(CH.sub.2).sub.n1(PO)(OR.sub.11).sub.2; sulphate; sulphonate; phosphate; phosphonate; (CH.sub.2).sub.n2[O(SO.sub.2)].sub.n3OR.sub.11; O(CH.sub.2).sub.n4(CO).sub.n5R.sub.11; (O).sub.n6(CH.sub.2).sub.n7(PO)(OR.sub.9).sub.2; (O).sub.n6(CH.sub.2).sub.n7SO.sub.2OR.sub.9; halogen; organosilanyl; organo-siloxanyl; or a sugar residue linked directly in an - or -mode via the anomeric oxygen to the benzotropolone system or via a linear or branched alkylene, alkenylene, alkadiene or alkatriene spacer (sugar-(CH.sub.2).sub.n(X.sub.1).sub.1 or 0-benzotropolone system, wherein n=1-10 and X.sub.1O; (CO); OCO; COO, NH; S; SO.sub.2); R.sub.1, R.sub.7 and R.sub.8 independently of one another are hydrogen; C.sub.1C.sub.12alkyl or C.sub.3-C.sub.12-cycloalkyl, which may be substituted by one or more E and/or interrupted by one or more D; C.sub.6-C.sub.20aryl, which may be substituted by one or more G; C.sub.4-C.sub.20heteroaryl, which may be substituted by one or more G, C.sub.2-C.sub.18alkenyl, C.sub.2-C.sub.18alkynyl, C.sub.7-C.sub.25aralkyl, or COOR.sub.9; COR.sub.9; CONR.sub.9R.sub.10; SO.sub.3R.sub.9; SO.sub.2R.sub.9; PO.sub.3(R.sub.9).sub.2; PO.sub.2(R.sub.9).sub.2; organosilanyl; organosiloxanyl; or a sugar residue linked directly in an - or -mode via the anomeric oxygen to the benzotropolone system or via a linear or branched alkylene, alkenylene, alkadiene or alkatriene spacer (sugar-(CH.sub.2).sub.n(X.sub.2).sub.1 or 0*, wherein n=1-10 and X.sub.2C(O); OCO*); R.sub.9 and R.sub.10 independently from each other are hydrogen; C.sub.1C.sub.18alkyl or C.sub.3-C.sub.12-cycloalkyl which may be substituted by one or more E and/or interrupted by one or more D; C.sub.6-C.sub.20aryl, which may be substituted by one or more G; C.sub.4-C.sub.20heteroaryl, which may be substituted by one or more G; organosilanyl; organosiloxany

Described is the use of benzotropolone and their derivatives, especially the compounds of formula (1); wherein R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 independently of one another are hydrogen; OH; C.sub.1-C.sub.30alkyl, C.sub.2-C.sub.30al-kenyl, C.sub.1-C.sub.30alkoxy, C.sub.3-C.sub.12cycloalkyl or C.sub.1C.sub.30hydroxyalkyl, which may be substituted by one or more E and/or interrupted by one or more D; C.sub.6-C.sub.20aryl, which may be substituted by one or more G; C.sub.4-C.sub.20heteroaryl, which may be substituted by one or more G, C.sub.2-C.sub.18alkenyl, C.sub.2-C.sub.18alkynyl, C.sub.7-C.sub.25aralkyl, CN, or COR.sub.17; C.sub.1-C.sub.30mono- or dialkylamino; COR.sub.9; COOR.sub.9; CONR.sub.9R.sub.10; CN; SO.sub.2R.sub.9; OCOOR.sub.9; OCOR.sub.9; NHCOOR.sub.9; NR.sub.9COR.sub.10; NH.sub.2; *(CO)NH(CH.sub.2).sub.n1(PO)(OR.sub.11).sub.2; (CO)O(CH.sub.2).sub.n1(PO)(OR.sub.11).sub.2; sulphate; sulphonate; phosphate; phosphonate; (CH.sub.2).sub.n2[O(SO.sub.2)].sub.n3OR.sub.11; O(CH.sub.2).sub.n4(CO).sub.n5R.sub.11; (O).sub.n6(CH.sub.2).sub.n7(PO)(OR.sub.9).sub.2; (O).sub.n6(CH.sub.2).sub.n7SO.sub.2OR.sub.9; halogen; organosilanyl; organo-siloxanyl; or a sugar residue linked directly in an - or -mode via the anomeric oxygen to the benzotropolone system or via a linear or branched alkylene, alkenylene, alkadiene or alkatriene spacer (sugar-(CH.sub.2).sub.n(X.sub.1).sub.1 or 0-benzotropolone system, wherein n=1-10 and X.sub.1O; (CO); OCO; COO, NH; S; SO.sub.2); R.sub.1, R.sub.7 and R.sub.8 independently of one another are hydrogen; C.sub.1C.sub.12alkyl or C.sub.3-C.sub.12-cycloalkyl, which may be substituted by one or more E and/or interrupted by one or more D; C.sub.6-C.sub.20aryl, which may be substituted by one or more G; C.sub.4-C.sub.20heteroaryl, which may be substituted by one or more G, C.sub.2-C.sub.18alkenyl, C.sub.2-C.sub.18alkynyl, C.sub.7-C.sub.25aralkyl, or COOR.sub.9; COR.sub.9; CONR.sub.9R.sub.10; SO.sub.3R.sub.9; SO.sub.2R.sub.9; PO.sub.3(R.sub.9).sub.2; PO.sub.2(R.sub.9).sub.2; organosilanyl; organosiloxanyl; or a sugar residue linked directly in an - or -mode via the anomeric oxygen to the benzotropolone system or via a linear or branched alkylene, alkenylene, alkadiene or alkatriene spacer (sugar-(CH.sub.2).sub.n(X.sub.2).sub.1 or 0*, wherein n=1-10 and X.sub.2C(O); OCO*); R.sub.9 and R.sub.10 independently from each other are hydrogen; C.sub.1C.sub.18alkyl or C.sub.3-C.sub.12-cycloalkyl which may be substituted by one or more E and/or interrupted by one or more D; C.sub.6-C.sub.20aryl, which may be substituted by one or more G; C.sub.4-C.sub.20heteroaryl, which may be substituted by one or more G; organosilanyl; organosiloxany

The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the -secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of -amyloid aggregates.

Provided are a novel compound, preparing method thereof, and use thereof as inhibitor of histone demethylase. The compound represented by Chemical Formula 1 has activity which inhibits histone demethylase and thus is capable of specifically and effectively inhibit activity of histone demethylase.

Provided are a novel compound, preparing method thereof, and use thereof as inhibitor of histone demethylase. The compound represented by Chemical Formula 1 has activity which inhibits histone demethylase and thus is capable of specifically and effectively inhibit activity of histone demethylase.